AOD-9604: Molecular Structure

Molecular Structure and Properties#

AOD-9604 is a synthetic hexadecapeptide (16 amino acids) derived from the C-terminal domain of human growth hormone (hGH). Its design was based on the identification of the hGH lipolytic domain, which resides in the C-terminal region of the 191-amino acid growth hormone molecule, distinct from the GH receptor binding site located in the N-terminal and central domains.

Amino Acid Sequence#

Full Sequence#

The complete sequence of AOD-9604 is:

H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH

This corresponds to hGH residues 176-191 with one critical modification: the N-terminal phenylalanine (Phe176 in native hGH) is replaced with tyrosine (Tyr). This substitution provides a convenient spectrophotometric handle for analytical detection (tyrosine absorbs at 280 nm) while maintaining biological activity.

Functional Domains#

Disulfide Bond Architecture#

A critical structural feature of AOD-9604 is the intramolecular disulfide bond formed between Cys7 and Cys14. This bond creates a cyclic loop encompassing residues 7 through 14 (Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys), constraining the peptide's three-dimensional conformation and contributing to its biological activity and structural stability.

The disulfide bond in AOD-9604 mirrors the Cys182-Cys189 disulfide bond present in native hGH. In the full-length growth hormone, this bond is part of the "mini-loop" structure in the C-terminal domain that defines the lipolytic region. Preservation of this structural motif in AOD-9604 is essential for maintaining the peptide's lipolytic activity.

Physicochemical Properties#

Molecular Formula Breakdown#

The molecular formula C78H123N23O23S2 accounts for:

• Carbon: 78 atoms from amino acid backbones, side chains, and aromatic rings
• Hydrogen: 123 atoms
• Nitrogen: 23 atoms from peptide bonds, arginine guanidinium groups, and amino terminus
• Oxygen: 23 atoms from carboxylate groups, peptide carbonyls, serine/glutamine/glutamic acid side chains
• Sulfur: 2 atoms from the two cysteine residues forming the disulfide bond

Relationship to Human Growth Hormone#

Structural Context within hGH#

Human growth hormone is a 191-amino acid protein with a molecular weight of approximately 22 kDa. Its three-dimensional structure consists of a four-helix bundle with two disulfide bonds:

• Cys53-Cys165 (large loop)
• Cys182-Cys189 (small loop, C-terminal mini-loop)

AOD-9604 corresponds to the last 16 residues of hGH, encompassing the C-terminal mini-loop defined by the Cys182-Cys189 disulfide. This region was identified as the lipolytic domain of hGH through deletion mapping and fragment studies.

Why the C-Terminal Fragment Lacks GH Receptor Binding#

The growth hormone receptor binding sites (Site 1 and Site 2) are located primarily in helices 1, 3, and 4 of hGH, involving residues in the N-terminal half of the molecule. The C-terminal region from which AOD-9604 is derived does not participate significantly in GH receptor contact. This structural separation explains why AOD-9604 retains lipolytic activity while completely lacking GH receptor binding, IGF-1 stimulation, and growth-promoting effects.

The N-Terminal Tyrosine Modification#

The replacement of Phe176 with Tyr in AOD-9604 is a deliberate design modification. In native hGH, position 176 is phenylalanine. The substitution to tyrosine:

• Adds a hydroxyl group to the aromatic ring (the only structural difference between Phe and Tyr)
• Enables UV spectrophotometric detection at 280 nm (phenylalanine does not absorb well at this wavelength)
• Does not significantly alter the peptide's biological activity or receptor interactions
• Facilitates radiolabeling studies (iodination of tyrosine is a standard technique)

Pharmacokinetic Properties#

Absorption#

AOD-9604 has been studied via multiple routes of administration:

Oral: The peptide has been administered orally in clinical trials. Peptides typically have very poor oral bioavailability (<1%) due to gastric acid degradation and enzymatic hydrolysis. However, some evidence suggests that the disulfide-bonded cyclic structure of AOD-9604 may confer partial resistance to gastrointestinal proteases.

Subcutaneous: The most common research route for peptides. Subcutaneous injection of AOD-9604 provides higher bioavailability than oral administration but involves first-pass metabolism through tissue peptidases.

Intra-articular: For the cartilage repair indication, direct injection into the joint space has been studied in animal models, providing high local concentration with minimal systemic exposure.

Distribution#

The distribution profile of AOD-9604 has not been extensively characterized. As a small peptide (1815 Da), it is expected to distribute widely in extracellular fluid but have limited blood-brain barrier penetration.

Metabolism#

AOD-9604 is metabolized through peptidase activity. The disulfide bond between Cys7 and Cys14 must be reduced before the cyclic portion can be fully degraded. Major metabolic pathways include:

• Aminopeptidase cleavage from the N-terminus
• Carboxypeptidase cleavage from the C-terminus
• Endopeptidase cleavage at various peptide bonds
• Disulfide bond reduction by glutathione and thioredoxin systems

Elimination#

Metabolic fragments are eliminated through renal clearance. The small size of AOD-9604 and its metabolites facilitates glomerular filtration.

Stability Considerations#

Chemical Stability#

AOD-9604's stability is influenced by several factors:

Disulfide bond integrity: The Cys7-Cys14 disulfide bond is essential for biological activity. Reduction of this bond (by thiol reagents, reducing conditions, or alkaline pH) inactivates the peptide. Conversely, exposure to oxidizing conditions can cause disulfide scrambling or formation of intermolecular disulfide bonds (oligomerization).

Proteolytic degradation: In solution, AOD-9604 is susceptible to degradation by contaminating proteases. Sterile handling and appropriate preservatives are important.

pH sensitivity: The peptide is most stable at slightly acidic pH (4.0-6.0). Alkaline conditions promote disulfide reduction and deamidation of asparagine/glutamine residues.

Storage Recommendations#

Analytical Characterization#

AOD-9604 can be characterized by several analytical methods:

• HPLC: Reverse-phase HPLC for purity assessment (>95% typical specification)
• Mass spectrometry: Expected MW 1815.12 Da; ESI-MS or MALDI-TOF for identity confirmation
• Amino acid analysis: Confirms residue composition
• Ellman's assay: Quantifies free thiols (should be near zero if disulfide is intact)
• Circular dichroism: Can assess secondary structure and disulfide integrity

Evidence Gaps#

• Complete pharmacokinetic profile in humans not published
• Oral bioavailability not precisely quantified
• Three-dimensional solution structure not determined by NMR or crystallography
• Whether the disulfide bond is essential for lipolytic activity vs. structural stability not definitively established
• Comparative stability under different formulation conditions not systematically studied

Related Reading#

• AOD-9604 overview and research guide
• Peptides similar to AOD-9604
• AOD-9604 research evidence